



Proteomics International

LABORATORIES LTD

ASX Release
27 October 2025

ASX code: PIQ

Quarterly Activities Report

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to provide the following update on its business activities for the three months to 30 September 2025 and subsequent to the period end.

Highlights include:

- **PIQ – Clinical certification for diagnostics laboratory:** ISO 15189 medical testing certification granted for Proteomics International’s Australian laboratory operations.
- **PIQ – Board and Management Transition:** Proteomics International’s Founder and Managing Director, Dr Richard Lipscombe to retire in February 2026. A specialist life sciences executive search firm has been engaged to recruit a new CEO.
- **Promarker®D – Diabetic Kidney Disease prediction**
 - PromarkerD launched nationally in Australia on 20 August, and is now accessible online or via referral from the majority of GP practices, with over 2,100 blood collection sites available.
 - CPT PLA billing code granted by American Medical Association supporting reimbursement activities
 - Simplified next-gen test system released that aligns closely with routine pathology workflows - performance metrics published in the *Journal of Applied Laboratory Medicine*.
 - Update on roll-out activities in USA, Australia and Rest of World.
- **Promarker®Eso – Esophageal Cancer diagnosis**
 - PromarkerEso launched nationally in Australia on 18 September, harnessing the same logistical and digital resources developed for PromarkerD.
 - New results show that the first-in-class blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy.
 - Results presented at the 21st ISDE World Congress for Esophageal Diseases and published in the journal *Diseases of the Esophagus*.
- **Promarker®Endo – Endometriosis diagnosis**
 - Preparations for launch continue as collaboration expanded with leading medical and research institutions.
- **OxiDx – Oxidative stress monitoring**
 - Peer-reviewed study published demonstrating OxiDx can detect oxidative stress and track muscle recovery after a horse race.

OPERATIONAL HIGHLIGHTS – ENABLING PRECISION MEDICINE

Proteomics International’s activities align with three strategic areas:

- I. Commercialisation of the Company’s pipeline of precision diagnostics
- II. Precision diagnostic tests in development
- III. Specialist accredited analytical services on a commercial basis

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Go-to-Market strategy for the Company's suite of novel diagnostic tests

Growth in telehealth and increased consumer demand for preventative care are creating sustained momentum for decentralised diagnostics, with the global telehealth market projected to reach US\$112 billion this year and US\$335 billion by 2032, recording a CAGR of 16.9%¹.

Proteomics International's Go-to-Market route embraces this appetite for digital health by using a clinician driven strategy direct to the consumer (both patient and General Practitioner). This path serves as a prelude to potential out-licensing to major industry players in the diagnostics sector, providing maximum optionality for strategic partnering by achieving first sales and building market recognition of each test.

Clinical Certification for Diagnostic Laboratory Operations

[ASX: 18 September] Proteomics International achieved a major milestone with ISO 15189 certification granted for its Australian laboratory operations. This medical testing certification represents a core component of the commercialisation and clinical use of the Company's suite of precision diagnostic tests, supporting the roll-out of its specialist laboratory developed tests in Australia, including PromarkerD (launched nationally 20 August) and PromarkerEso (launched nationally 18 September) [see PIQ Annual Report ASX: 27 August].

ISO 15189 is the global standard specifically developed for medical laboratories, outlining the quality management and technical requirements needed to ensure accurate and dependable test results. Certification was granted by the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of Australasia (RCPA) following a comprehensive audit of Proteomics International's Western Australian laboratory facilities, systems, and processes.

These certifications ideally position Proteomics International to offer both its in-house developed tests, and to commercialise other third-party specialist tests that are emerging across the globe. As precision medicine starts to become a reality for patients, each pathway offers compelling potential new revenue streams for the Company.

PRECISION DIAGNOSTIC TESTS – THE PROMARKER® PIPELINE

Proteomics International develops novel precision health and predictive diagnostic tests using its proprietary biomarker discovery platform called Promarker®. This disruptive technology searches for protein 'fingerprints' in a sample and can identify protein biomarkers that distinguish between people who have a disease and people who do not, using only a standard blood test. It is a powerful advancement on genetic testing. The Promarker platform technology has broad applicability and is being used to produce multiple new diagnostic tests to address significant unmet medical and commercial needs.



¹ www.fortunebusinessinsights.com/industry-reports/telemedicine-market-101067

Promarker®D – predicting diabetic kidney disease

Promarker®D is a blood test to predict the onset of diabetes-related chronic kidney disease (DKD) up to four years before symptoms appear. It provides a significant advancement in diabetes management by enabling early detection and intervention, which are crucial for preventing or delaying the progression of this serious complication to end stage renal disease (leading to dialysis or kidney transplant).

Diabetes affects over 537 million people worldwide, and chronic kidney disease is a major complication, leading to severe health outcomes and increased mortality².

American Medical Association (AMA) grants next-generation Promarker®D test a dedicated billing code

[ASX: 3 July] As reported in the last Quarterly Activities Report, Proteomics International announced the assignment of a dedicated CPT PLA reimbursement code (0579U) by the AMA for the next-generation of the PromarkerD test system. The Centers for Medicare and Medicaid Services (CMS) will publish its pricing for the test in the coming weeks, following its review meeting in September.

A CPT PLA code uniquely identifies a test for the testing laboratory, enabling healthcare providers to order the test, facilitates a billing pathway for payers, and permits monitoring of test usage. The newly-approved code is effective for claims submitted after 1 October 2025, with formal reimbursement pricing to become effective from 1 January 2026. In the interim PromarkerD is for sale in the USA at US\$391 self-pay (see below).

Next-gen Promarker®D test system released for predicting DKD

[ASX: 24 July] The Company announced the successful development and release of its next-generation PromarkerD test system, with the performance metrics of the test published in the *Journal of Applied Laboratory Medicine*. These results were also presented as a Late Breaking Abstract at the 85th Scientific Sessions of the American Diabetes Association, the largest gathering of diabetes professionals in the world, as part of the US launch of PromarkerD [ASX: 20 and 23 June].

Simplified without compromising accuracy, the next-gen version of the test has been engineered as a high-throughput immunoassay that aligns closely with routine pathology workflows. The key performance data matches previously published performance identifying 86% of individuals at risk of DKD, all missed by standard tests.

Nationwide launch of Promarker®D in Australia

PromarkerD was launched across Australia at the Australasian Diabetes Congress, 20-22 August, Gold Coast, where the Company also presented its latest results and hosted sessions with experts in the field of diabetes care. This built upon the earlier pilot launch in Western Australia and the Northern Territory on World Kidney Day [ASX: 13 March] which enabled the optimisation of sample collection logistics, refining of the digital marketing campaign, and engagement with GP practices. Diabetes affects 1.5 million adults in Australia.

Update on roll-out of Promarker®D in Australia

- *PromarkerD was launched nationwide across Australia on the 20th August and first sales have been achieved.*
- The test is available to patients via parallel direct-to-consumer (DTC) channels [see also PIQ Annual Report ASX: 27 August]:
 - Digital health via the Company's www.myTEST.health web portal;
 - GP referral, with the PromarkerD pathology request form now embedded into the leading General Practice management software Bp Premier (from Best Practice Software) used in two-thirds of Australian practices.

² International Diabetes Federation 2021

- Blood collection is available from over 2,100 collection sites across Australia facilitated by the Healius Pathology network (including Dorevitch Pathology, Lavery Pathology, QML Pathology and Western Diagnostic Pathology).
- The clinical testing of patient samples is performed to ISO 15189 laboratory standard within Proteomics International's newly certified laboratory [ASX: 18 September].
- Critical ongoing steps to ensure the success of the Go-to-Market strategy are:
 - refining the sales and marketing to target Australian clinicians and patients motivated to adopt the test;
 - engaging with key stakeholders including Key Opinion Leaders (KOLs), primary care networks and patient advocacy groups to build awareness and adoption of the test.
- Key messaging revolves around highlighting the early prediction and prevention as core differentiators versus the current standard of care tests (estimated glomerular filtration rate (eGFR), albumin-to-creatinine ratio (ACR)) that are not predictive.
- The Company anticipates sales volumes in Australia will be limited until GPs become familiar with the test and prior to reimbursement being available, nonetheless, they continue to provide essential learnings for the US roll-out.

Update on roll-out of Promarker®D in the USA

- *PromarkerD was launched in the USA on the 20th June and first sales have been achieved.*
- The test is available to patients via parallel direct-to-consumer (DTC) channels, as for Australia [see also PIQ Annual Report ASX: 27 August]:
 - Digital health via the Company's www.myTEST.health web portal;
 - Primary Care Physician (PCP) referral.
- Blood collection is available from 6 selected sites in California in the major population areas of Orange County, Los Angeles County, San Diego County and Ventura County, covering approximately 16 million people. The Company continues to add additional blood collection sites.
- The clinical testing of patient samples is performed at Proteomics International USA's Clinical Laboratory Improvement Amendment (CLIA) certified reference laboratory in Irvine, California [ASX: 28 February].
- Critical ongoing steps to ensure the success of the Go-to-Market strategy are:
 - refining the sales and marketing to target US clinicians and patients motivated to adopt the test;
 - engaging with key stakeholders including KOLs, primary care networks (see Events and Marketing below) and patient advocacy groups to build awareness and adoption of the test;
 - engaging with private insurers ahead of the CPT PLA reimbursement code 0579U becoming effective in January 2026.
- Key messaging revolves around highlighting the early prediction and prevention as core differentiators versus the current standard of care tests (eGFR, ACR) that are not predictive.
- The Company anticipates sales volumes will be low initially as PCPs become familiar with the test and prior to reimbursement being available.

Update on commercialisation of Promarker®D in Rest of World

- Sales are continuing in Puerto Rico and the Dominican Republic via licence partner Omics Global Solutions (OGS). OGS continues to receive reimbursement of the test from insurers in the US territory of Puerto Rico.
- Proteomics International is also in discussion with OGS to extend its PromarkerD licence agreement to include Mexico.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

- For Europe, Proteomics International is engaged directly with potential central Reference Laboratories to run the PromarkerD test.
- Following reassessment of market opportunities, the Company has ended its Distributor Agreements with Apacor for Great Britain [ASX: 15 February 2023] and Eurobio for France [ASX: 24 June 2024]. These distributor relationships no longer aligned with Proteomics International's transition to focus on the use of central Reference Laboratories.

Further information about Promarker®D is available through the www.PromarkerD.com web portal.

Proteomics International recommends that patients concerned about DKD seek advice from their doctors. Country specific use of this product is subject to the relevant regulatory approvals.

Further information on DKD is available through the Company's www.myTEST.health web portal.

Promarker®Eso – diagnosing esophageal cancer

Promarker®Eso is a blood test that detects specific protein changes to rule out esophageal adenocarcinoma (EAC). A major risk factor for esophageal cancer is chronic acid reflux or 'GERD' (gastroesophageal reflux disease), and it is estimated that up to 20% of the USA population³ and 11% of patients visiting GP clinics in Australia⁴ have GERD. EAC is the most common form of esophageal cancer, with the five-year survival rate for EAC being less than 20% because it is frequently diagnosed too late for effective treatment.


Current gold-standard screening for the disease requires a specialist endoscopy, an invasive procedure that costs US\$2,750 in the United States⁵ where total expenditure on treating EAC was US\$2.9 billion in 2018. In the USA 6.1 million endoscopies with biopsy are performed annually⁶, but despite this up to 90% of EAC cases continue to go undetected⁷.

Promarker®Eso blood test detects early stages of Esophageal Adenocarcinoma with high accuracy

[ASX: 8 September] New results show that the first-in-class PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma (EAC) with high accuracy.

The study analysed 350 people across two independent cohorts and PromarkerEso exhibited excellent diagnostic accuracy for all stages of EAC. Results demonstrated that increasing severity of disease is significantly correlated with increasing PromarkerEso test scores ($p < 0.0001$). The results from the study were published online in the journal *Diseases of the Esophagus*, the official journal of The International Society for Diseases of the Esophagus (ISDE).

Figure. PromarkerEso test performance. The study compared 89 healthy controls against patients with esophageal adenocarcinoma (EAC) samples of known stage (stage I: n=16; stage II: n=23; stage III: n=16, stage IV: n=3).



³ www.yalemedicine.org/conditions/gerd-gastroesophageal-reflux-disease

⁴ www.racgp.org.au/afp/2015/october/gastro-oesophageal-reflux-disease-gord-in-australia

⁵ www.newchoicehealth.com/endoscopy/cost

⁶ *Gastroenterology* (2019): doi: 10.1053/j.gastro.2018.08.063

⁷ *Gastroenterology* (2022): doi: 10.1053/j.gastro.2022.03.037

Promarker[®]Eso launched in Australia at World Conference

[ASX: 19 September] PromarkerEso was formally launched in Australia at the 21st ISDE World Congress for Esophageal Diseases, held in Brisbane, 18-20 September 2025. The findings (see above) from the detection of early-stage EAC study were also presented at the conference. PromarkerEso is now available across Australia to patients through a telehealth consultation, and by physician referral. Both patients and physicians can gain access to the test via the www.myTEST.health website.

Promarker[®]Eso launch status update:

- *The PromarkerEso test launched nationwide across Australia on the 18th September, harnessing the same logistical and digital resources developed for PromarkerD, and first sales have been achieved.*
- The test is available to patients via parallel direct-to-consumer (DTC) channels:
 - Digital health via the Company's www.myTEST.health web portal;
 - GP referral, with the PromarkerEso pathology request form now embedded into the leading General Practice management software Bp Premier (from Best Practice Software) used in two-thirds of Australian practices.
- Blood collection is available from over 2,100 collection sites across Australia facilitated by the Healius Pathology network.
- The clinical testing of patient samples is performed within Proteomics International's certified laboratory in line with ISO 15189 standards.
- Continuing to build awareness of the test with clinicians, KOL's and advocacy groups in response to the growing incidence and awareness of GERD.
- Preparing to tech-transfer the test to Proteomics International's CLIA certified USA laboratory prior to launch in the US market in the coming months.
- The launch of PromarkerEso in the USA will follow the same regulatory (CLIA certified laboratory developed test) and reimbursement (PLA code via CMS) pathways that the Company has successfully followed for PromarkerD.

Further information about Promarker[®]Eso is available through the www.PromarkerEso.com web portal.

Proteomics International recommends that patients concerned about chronic acid reflux seek advice from their doctors. Country specific use of this product is subject to the relevant regulatory approvals.

Further information on chronic acid reflux is available through the Company's www.myTEST.health web portal.

Promarker[®]Endo – diagnosing endometriosis

Promarker[®]Endo is a blood test for the early diagnosis of endometriosis. This is a debilitating disease that affects one in nine women and girls worldwide⁸, often starting in adolescence. Endometriosis can cause symptoms such as pelvic pain, painful periods and infertility and occurs when tissue similar to the lining of the uterus grows in other parts of the body where it does not belong.

Currently there is no simple test for endometriosis and diagnosis takes an average of seven years. This delay is multifactorial, with a key contributor being the reliance on surgery, specifically laparoscopy. The cost of this surgical procedure varies widely, with direct costs ranging from \$2,000 to \$15,000⁹ and average out-of-pocket (private) costs of \$3,690 in Australia¹⁰, and average direct costs of US\$21,268 and average out-of-pocket costs of US\$4,923 in the USA^{11,12}. The total burden of endometriosis costs in Australia alone are estimated as \$9.7 billion each year¹³.

⁸ World Health Organisation (WHO.org); www.who.int/news-room/fact-sheets/detail/endometriosis

⁹ www.abc.net.au/news/2023-03-14/the-cost-of-an-endometriosis-diagnosis/102031662

¹⁰ medicalcostsfinder.health.gov.au/service/?id=H14&mode=H

¹¹ Human Reproduction (2016); doi.org/10.1093/humrep/dev335

¹² endometriosis.net/clinical/cost-laparoscopy-surgery

¹³ endometriosisaustralia.org

Promarker®Endo collaboration expanded with University of Melbourne and Royal Women's Hospital

[ASX: 15 October] The expanded research agreement is in two parts: to enable additional clinical validation studies, and for the development of a future tissue specific diagnostic test for endometriosis.

Promarker®Endo next steps:

- PromarkerEndo commercialisation is targeted for launch in H2 CY25 in Australia, with other jurisdictions to follow.
- The launch will leverage the Company's established Go-To-Market strategies for its other Promarker tests, utilising both clinical and digital direct-to-consumer channels in Australia.
- Analytical methodology is being adapted for use in a clinical environment under the ISO 15189 (clinical testing) pathway.
- Partnering discussions are advancing in key markets for licensing in women's health and fertility.
- Continuing to build awareness of the test with clinicians, KOLs and advocacy groups in response to the upsurge in demand for better diagnosis of endometriosis.

OxiDx – monitoring muscle damage and recovery

Oxidative stress is implicated in over 70 health conditions, with levels often reflective of a person's health condition¹⁴. Target applications include high-performance athletes and the horse racing industry, where the OxiDx test can be used to measure levels of muscle damage via a simple fingerpick blood sample to detect protein biomarkers in the blood.


In professional sports, muscle injuries are the most frequent cause of incapacity, accounting for up to 55% of all injuries. Similarly, in the horse racing industry, 85% of thoroughbreds sustain at least one injury during their two- and three-year-old racing seasons¹⁵, potentially as a result of undetected muscle injuries. In 2023, \$1.2 billion was spent on treating potentially avoidable sports injuries in Australia¹⁶.

OxiDx test detects muscle damage in thoroughbred racehorses

[ASX: 14 July] Ground breaking results published in the journal *Veterinary Science and Medicine* showed OxiDx can track muscle recovery after a horse race.

Results across the 34 horses studied indicated, for most, levels of oxidative stress peaked 48 hours post-race and remained elevated for up to five days. However, individual variability was significant, with some horses showing prolonged recovery times of over seven days. This variability emphasises the importance of monitoring the recovery of each horse to prevent premature training or competition resumption.

Figure. OxiDx test performance. Heatmap depicting oxidative stress levels that are below or above the baseline value for 34 horses each day after completing the race.



¹⁴ Doi: 10.1373/clinchem.2005.061408

¹⁵ Animals (2023); doi: 10.3390/ani13030490

¹⁶ Australian Institute of Health and Welfare (2023): Economics of sports and physical activity participation and injury

OxiDx next steps:

- Exploring commercial opportunities in high performance athletes, sports teams and the horse racing industry in Australia and USA.
- Clinical utility study in racehorses being finalised to further validate the ability of the OxiDx test to improve performance and reduce risk of muscle damage.
- Proteomics International aims to launch the new test in Australia through its OxiDx subsidiary in H2 CY25, and then expand into the USA via the Company's US Reference Laboratory.

ANALYTICAL SERVICES

The demand for analytical services remains steady, covering the areas of pharmacokinetic testing, biosimilars and proteomics analysis, food testing, and biomarker discovery on a contract basis. The Company continues to look for opportunities to grow these revenues, targeting the clinical trials sector for both pharmacokinetic testing and the development of companion/complementary diagnostics (CDx) through biomarker analysis.

EVENTS AND MARKETING

Proteomics International launched a new version of its website: www.proteomics.com.au
The revamped site integrates and bridges the Company's digital suite, comprising: www.PromarkerD.com, www.PromarkerEso.com, and www.myTEST.health

Recent Events

During the quarter, Proteomics International was represented at several significant industry and clinical/scientific conferences:

- **30th General Practice Conference & Exhibition (GPCE) Melbourne;** 11-13 July, Melbourne, Victoria
- **19th Bioshares Biotech Summit;** 7-8 August, Hobart, Tasmania
- **Australasian Diabetes Congress;** 20-22 August, Gold Coast, Queensland
- **60th ANZSN Congress (Australia New Zealand Society of Nephrology);** 30 August-3 September, Perth, Western Australia
- **Combined Biological Sciences Meeting;** 19 September, Perth, Western Australia
- **21st ISDE World Congress (International Society for Diseases of the Esophagus);** 18-20 September, Brisbane, Queensland

Proteomics International in the media

The Company's diagnostic pipeline, commercialised products, ongoing commercialisation activities, and publication of clinical findings continue to receive widespread media coverage including from The Sydney Morning Herald, The Age, The Brisbane Times, MedicalXpress, Newsreel, AgriFutures and 360Dx¹⁷.

Forthcoming Events

For the current quarter, Proteomics International will be represented at the following events and conferences:

- **Clinical Association of California Endocrinologists (CACE) 2025 Hot Topics in Diabetes and Endocrinology,** 4 October, Bakersfield, CA, United States
- **2025 SoCal Region 1 (Los Angeles County) & SoCal Region 2 (Orange County) Annual Scientific Meeting,** 5 October, Los Angeles, CA, United States
- **Family Medicine Experience (FMX) 2025,** 6-8 October, Anaheim, CA, United States
- **Ausbiotech** 24-25 October, Melbourne, Victoria
- **2025 SoCal Region 3 (San Diego County) Annual Scientific Meeting,** 25 October, La Jolla, CA, United States
- **California Primary Care Association Annual Conference,** 30-31 October, San Diego, CA, United States

¹⁷ <https://investor.proteomics.com.au/newsroom/inthemedial/news-media/>

- **30th General Practice Conference & Exhibition (GPCE) Perth**, 8-9 November, Perth, WA
- **Endometriosis and Pelvic Pain in Primary Care: Practical Management and Triage**, 12 November, Perth, WA
- **Royal Australian College of General Practitioners (RACGP) GP25**, 14-16 November, Brisbane, Qld

These events align with the Company's objective of actively engaging with potential users of its technology to foster awareness, adoption and uptake of its novel diagnostic tests.

The **Annual General Meeting** of Proteomics International Laboratories Ltd will be held on Friday 21 November 2025, at the Harry Perkins Institute of Medical Research, Perth, Western Australia.

All PIQ announcements and related shareholder information are available from the Company's website¹⁸.

FINANCIAL AND CORPORATE HIGHLIGHTS

Proteomics International's business model is to commercialise its pipeline of novel diagnostic tests, exemplified by Promarker®D, Promarker®Endo, Promarker®Eso and OxiDx, in major markets across the world, and offset the cash burn from R&D and product development through its analytical services revenue, coupled with the R&D tax incentive rebate. This diversified model enables the group to make optimum use of its resources.

Proteomics International receives major funding boost to expand its precision diagnostics capability

[ASX: 1 July] As reported in the last Quarterly Activities Report, the WA Proteomics Facility, a collaborative Public Private Partnership jointly managed by Proteomics International and The University of Western Australia, will enjoy a \$6 million funding boost.

The funds will be used to add new state-of-the-art instruments to accelerate advances in precision medical diagnostics and agricultural proteomics, which will enable higher throughput clinical testing. This expansion comprises a \$4 million co-investment over three years by the WA State Government and Bioplatfroms Australia, plus \$1 million each from UWA and Proteomics International.

Board and Management Transition

[ASX: 9 September] In close consultation with the Board, Managing Director, Dr Richard Lipscombe, has advised of his intention to retire in February 2026. The timing will coincide with his 25th anniversary as Founder and Managing Director of Proteomics International. To support the transition, the Board has appointed a specialist life sciences executive search firm to recruit a new CEO with global experience in diagnostics, medical technology and digital health commercialisation. Dr Lipscombe will continue as Managing Director until his successor is appointed, and the transition is complete.

[ASX: 7 October] The company announced the appointment of David Wood as Joint Company Secretary who will serve alongside current Company Secretary Timothy Luscombe.

[ASX: 14 October] Proteomics International announced the appointment of Ms Vicki Robinson to its Board as an independent non-executive director. Ms Robinson brings over 20 years' experience in senior executive, legal, transactional, and commercial management roles and has extensive non-executive director experience across diverse industries.

Revenue & Expenditure

Proteomics International achieved cash receipts from customers for the September quarter of \$1,864,000 (June quarter: \$201,000), which includes a non-recurring receipt of \$1.71 million linked to the WA Proteomics Facility collaborative Public Private Partnership jointly managed by Proteomics International and The University of Western Australia (see above). The net operating cash outflow for the September quarter was \$0.8 million (cash outflow in June quarter: \$3.2 million). Expenditure centred on the following areas:

¹⁸ <https://investor.proteomics.com.au/investors/asx/>

- Business development and commercialisation costs for the rollout of PromarkerD and PromarkerEso
- Acceleration of the Go-to-Market strategies for PromarkerEndo and PromarkerEso
- R&D for projects in the Promarker® diagnostics pipeline

ASX Listing Rule 4.7C

Payments at item 6.1 of Appendix 4C of \$164,000 relate to normal remuneration of Executive and Non-Executive Directors.

Cash Position

At 30 September, the Company had cash reserves of \$10.0 million (30 June: \$11.0 million). The balance sheet will be further strengthened by a forecast Research and Development tax incentive rebate of circa \$2 million expected to be received in 1H FY26.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Proteomics International (Europe)
Plesmanweg 9, 7602 PD Almelo
The Netherlands
T: +31 85 40 11 173
E: Europe@PromarkerD.eu

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Proteomics International Laboratories Ltd

ABN

78 169 979 971

Quarter ending ("current quarter")

30 September 2025

Consolidated statement of cash flows	Current Quarter \$A'000	Year to date \$A'000
1. Cash flows related to operating activities		
1.1 Receipts from Customers	1,864	1,864
1.2 Payments for		
(a) research & development	(1,031)	(1,031)
(b) product manufacturing & operating costs	(346)	(346)
(c) advertising & marketing	(378)	(378)
(d) leased assets	0	0
(e) staff costs	(735)	(735)
(f) administration & corporate costs	(234)	(234)
1.3 Dividends received (see note 3)	0	0
1.4 Interest received	91	91
1.5 Interest & other costs of finance paid	0	0
1.6 Income taxes paid	0	0
1.7 Government grants & tax incentives	0	0
1.8 Other (provide details if material)	0	0
1.9 Net cash from / (used in) operating activities	(769)	(769)
2. Cash flows related to investing activities		
2.1 Payments to acquire:		
(a) entities	0	0
(b) businesses (see item 10)	0	0
(c) property, plant & equipment	(73)	(73)
(d) investments	0	0
(e) intellectual property	0	0
(f) other non-current assets	0	0
2.2 Proceeds from disposal of:	0	0
(a) entities	0	0
(b) businesses (see item 10)	0	0
(c) property, plant & equipment	0	0
(d) investments	0	0
(e) intellectual property	0	0
(f) other non-current assets	0	0
2.3 Cash flows from loans to other entities	0	0
2.4 Dividends received (see note 3)	0	0
2.5 Other (provide details if material)	0	0
2.6 Net cash from / (used in) investing activities	(73)	(73)

Consolidated statement of cash flows	Current Quarter	Year to date
	\$A'000	\$A'000
3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	0	0
3.2 Proceeds from issue of convertible debt securities	0	0
3.3 Proceeds from exercise of options	0	0
3.4 Transaction costs related to issues of equity securities or convertible debt securities	(133)	(133)
3.5 Proceeds from borrowings	0	0
3.6 Repayment of borrowings	0	0
3.7 Transaction costs related to loans & borrowings	0	0
3.8 Dividends paid	0	0
3.9 Other (provide details if material)	(43)	(43)
3.10 Net cash from / (used in) financing activities	(176)	(176)
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash & cash equivalents at beginning of period	11,037	11,037
4.2 Net cash from / (used in) operating activities (see 1.9 above)	(769)	(769)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(73)	(73)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(176)	(176)
4.5 Effect of movement in exchange rates on cash held	0	0
4.6 Cash & cash equivalents at end of quarter	10,019	10,019
5. Reconciliation of cash & cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current Quarter	Previous Quarter
	\$A'000	\$A'000
5.1 Bank balance	2,953	1,620
5.2 Cash deposits	7,066	9,417
5.3 Bank overdrafts	0	0
5.4 Other (provide details)	0	0
5.5 Cash & cash equivalents at end of quarter (should equal item 4.6 above)	10,019	11,037
6. Payments to related parties of the entity & their associates		Current Quarter
		\$A,000
6.1 Aggregate amount of payments to related parties and their associates included in item 1		164
6.2 Aggregate amount of payments to related parties and their associates included in item 2		0
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments		
Payments at 6.1 relate to normal remuneration of Executive and Non-Executive Directors		

For personal use only

7. Financing facilities available	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	0	0
7.2 Credit standby arrangements	0	0
7.3 Other(please specify)	0	0
7.4 Total financing facilities	0	0
7.5 Unused financing facilities available at quarter end		0
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. N/A		
8. Estimated cash outflows for next quarter		
8.1 Net cash from / (used in) operating activities (see 1.9 above)		\$A'000 (769)
8.2 Cash and cash equivalents at quarter end (Item 4.6)		10,019
8.3 Unused financing facilities available at quarter end (Item 7.5)		0
8.4 Total available funding (Item 8.2 + Item 8.3)		10,019
8.5 Estimated quarters of funding available at quarter end (Item 8.4 divided by Item 8.1)		13.0*
<i>*Excludes R&D tax incentive rebate of circa \$2 million expected to be received in the December quarter.</i>		
8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:		
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?		
Answer:		
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?		
Answer:		
8.6.3 Does the entity expect to be able to continue its operations and to meet it's business objectives and, if so, on what basis?		
Answer:		
Note: where item 8.5 is less than 2 quarters, all of the questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.		

For personal use only

Compliance Statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 27 October 2025

Authorised by: The Board
(Name the body or officer authorising release - see note 4)

Notes

1. The quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entities activities for the past quarter, how they have been financed and the effect this has had on the cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee-eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.